Okyanos seeks to render obsolete the label that doctors use to refer to chronic coronary artery disease patients as “no-option.” These “no option” patients who have had heart attacks and/or stents but still have deteriorating heart function are referred to in the medical world as “no-option” because no other interventions exist to treat them, until now. Okyanos introduces a new standard of care and a better quality of life to patients with “no-option” coronary artery disease (CAD) via cardiac stem cell therapy.
No-option cardiac patients typically are diagnosed with chronic coronary artery disease and can no longer be revascularized using conventional therapy of angioplasty/stent or bypass surgery. The longevity and quality of life of these patients are uncertain if their condition cannot be improved. The current treatments for patients who cannot be revascularized with standard care are limited to medication, transmyocardial laser revascularization (TMR) and/or enhanced external counterpulsation (EECP), and heart transplant.
Okyanos offers a new treatment to the “no-option” patient using the delivery of adipose-derived stem and regenerative cells (ADRCs) to the heart. The ADRCs assist the heart to repair tissue that is either wounded by a heart attack or diseased. The most important observation made by researchers has been that a certain type of stem cell, called a mesenchymal stem cell, grows new blood vessels in the heart, known as angiogenesis. The new blood vessels have been shown to support and improve heart function.
To date, nearly 1,000 patients have been treated in clinical trials with “mesenchymal” cells after heart attacks or with chronic coronary artery disease. The sum of these results have shown strong signs of efficacy and the more recent trials with more advanced cell mixtures and improved isolation methods, such as ADRCs, have shown better results than the first generation of trials.
You can learn more about cardiac stem cell therapy for chronic coronary artery disease and our vision at Okyanos, by watching this video where I discuss it in more detail.